^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Maxillary Sinus Carcinoma

4ms
Ameloblastic Carcinoma of the Maxilla: A Rare Case Report and Review of Literature from 1948 to 2021. (PubMed, Int J Surg Pathol)
This histopathologic and molecular profile supported the diagnosis of ameloblastic carcinoma. There has been no evidence of disease recurrence or metastasis eleven months after the initial diagnosis.
Review • Journal
|
BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • STK11 (Serine/threonine kinase 11) • CDKN2A (Cyclin-dependent kinase inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • MTAP (Methylthioadenosine Phosphorylase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • KRT19 (Keratin 19)
|
BRAF wild-type
5ms
NCI-2021-13901: Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Stage III-IVB Head and Neck Cancer (clinicaltrials.gov)
P1, N=36, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | Trial completion date: Feb 2025 --> Jun 2026 | Trial primary completion date: Feb 2025 --> Jun 2026
Enrollment open • Trial completion date • Trial primary completion date
|
PTEN (Phosphatase and tensin homolog) • AKT1S1 (AKT1 Substrate 1)
|
cisplatin • ipatasertib (RG7440)
6ms
The role of the WNT signaling pathway in the maxillary sinus squamous cell carcinoma. (PubMed, Med Oncol)
Our findings take attention to the dysregulations of the WNT signaling pathway that may support maxillary sinus carcinogenesis. The results will pave the way for further studies that investigate the therapy target potential of the WNT signaling pathway in this rare cancer.
Journal
|
BCL9 (BCL9 Transcription Coactivator)
8ms
NCI-2021-13901: Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Stage III-IVB Head and Neck Cancer (clinicaltrials.gov)
P1, N=46, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Jan 2022 --> Apr 2022
Trial initiation date
|
PTEN (Phosphatase and tensin homolog) • AKT1S1 (AKT1 Substrate 1)
|
cisplatin • ipatasertib (RG7440)
9ms
New P1 trial
|
PTEN (Phosphatase and tensin homolog) • AKT1S1 (AKT1 Substrate 1)
|
cisplatin • ipatasertib (RG7440)
1year
Rare case of metastatic adenocarcinoma to the maxillary sinus. (PubMed, BMJ Case Rep)
The patient is undergoing chemoradiation therapy for palliation of his symptoms. Clinicians should be aware of this potentional site of metastatic disease and suspect the diagnosis in a timely manner to avoid delays in making a diagnosis.
Clinical • Journal
|
CDX-2 • MUC2
1year
Locally advanced undifferentiated sarcomatoid carcinoma of the right maxillary sinus with PDCD6-TERT fusion: A rare case report. (PubMed, Oral Oncol)
He received TPF regimen induction chemotherapy combined with anti-PD1 inhibitor and radiotherapy. The effect of treatment was good.
Clinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)